Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：1
|
作者：
Cerbone, L. [1 ]
Di Nunno, V. [2 ]
Carril, L. [1 ]
Benchimol-Zouari, A. [1 ]
Flippot, R. [1 ]
Silva, C. Alves Costa [1 ]
Colomba-Blameble, E. [1 ]
Guida, A. [3 ]
Derosa, L. [1 ]
Escudier, B. [1 ]
Albiges, L. [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Osped Bellaria, Oncol Med, Bologna, Italy
[3] Osped Santa Chiara Terni, Med & Traslat Oncol, Terni, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
743P
引用
收藏
页码：S577 / S577
页数：1
相关论文
共 50 条
  • [1] Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
    Keeler, Molika Emmeline
    Kessler, Elizabeth Riley
    Bernard, Brandon
    Weisdack, Sarah
    Breaker, Kathryn M.
    Wold, Mali
    Ertz, Donna
    Weitzenkamp, David
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC).
    Xu-Vuillard, Alexandre
    Jouinot, Anne
    Pudlarz, Thomas
    Blanchet, Benoit
    Huillard, Olivier
    Joly, Charlotte
    Tournigand, Christophe
    Oudard, Stephane
    Medioni, Jacques
    Vano, Yann-Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)
    Verzoni, E.
    Ferro, S.
    Procopio, G.
    Cova, A.
    Ratta, R.
    Raimondi, A.
    Sepe, P.
    Squarcina, P.
    Lalli, L.
    Huber, V.
    Rinchai, D.
    Bedognetti, D.
    Rivoltini, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
    Martini, Dylan J.
    Shabto, Julie M.
    Liu, Yuan
    Carthon, Bradley Curtis
    Speak, Alexandra
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Ogan, Kenneth
    Harris, Wayne
    Master, Viraj A.
    Kucuk, Omer
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C)
    Kline, Meredith R.
    Martini, Dylan J.
    Liu, Yuan
    Shabto, Julie M.
    Carthon, Bradley Curtis
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Yantorni, Lauren Beth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Treatment (trx) Modalities After a Front Line Targeted Therapies in Patients (pts) With Metastatic Renal Cell Carcinoma (mRCC)
    Levy, A.
    Menard, J.
    Albiges-Sauvin, L.
    Loriot, Y.
    Massard, C.
    Blesius, A.
    Di Palma, M.
    Fizazi, K.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S521 - S521
  • [10] Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.
    Hirsch, Laure
    Chanza, Nieves Martinez
    Farah, Subrina
    Flippot, Ronan
    Rathi, Nityam
    Collier, Katharine
    de Velasco, Guillermo
    Seront, Emmanuel
    Beuselinck, Benoit
    Xu Wenxin
    Bowman, Isaac Alexander
    Lam, Elaine Tat
    Dzimitrowicz, Hannah Elizabeth
    Zakharia, Yousef
    McKay, Rana R.
    Bilen, Mehmet Asim
    Albiges, Laurence
    Xie Wanling
    Harshman, Lauren C.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345